Dallas-based businesswoman, philanthropist, volunteer and environmentalist Lyda Hill has pledged $50 million to MD Anderson’s Moon Shots Program. Her gift is the largest single private philanthropic contribution to date in support of this ambitious effort to dramatically reduce cancer deaths. Read more about this transformational gift and the program it supports.
As young donors practice the art of giving, they set an example for all generations to follow. Read how two girls share their resources to help fund cancer research at MD Anderson.
MD Anderson has launched an all-out assault on cancer: the Moon Shots Program. This comprehensive initiative will integrate efforts across the entire cancer continuum — from prevention and early detection to treatment and survivorship — in a pioneering plan to drastically reduce cancer mortality and improve quality of life after cancer.
A $1 million philanthropic contribution from AT&T seeds a new telesurgery program at MD Anderson. It will help close the distance between patients in rural, underserved areas and the institution's surgical oncology experts.
Barely able to walk and 700 miles from home, Sam Davenport was forced to accept defeat. But the severe pain from riding his bicycle thousands of miles and pushing his body beyond its physical limits didn’t end his personal quest to fight cancer.
Read about John Weinstein, M.D., Ph.D., who is using computer-generated tools such as clustered heat maps to create molecular portraits of cancer that can lead to personalized therapies.
Read about Crave Cupcakes partnership with MD Anderson's Childrens Cancer Hospital's Arts in Medicine program. The popular Houston-area bakery is partnering with Arts in Medicine, a program that offers patients at MD Anderson Children’s Cancer Hospital a creative outlet.
Read about John Mendelsohn, M.D., and his passion for Making Cancer History®. He will step down from his role as MD Anderson’s third president to resume personalized cancer therapy research. He and his wife, Anne, were honored at a recent celebration of the institution’s 70th anniversary.
Read how philanthropy is helping transform cancer care, research, prevention, detection and more at The University of Texas MD Anderson Cancer Center. The current issue of Promise, brought to you by the Development Office, offers stories of generosity, courage and discovery.
The current issue of Promise, brought to you by the Development Office, offers stories of generosity, courage and discovery, plus the latest survey results from U.S. News and World Report’s “America’s Best Hospitals” survey ranking MD Anderson once again as No. 1 in cancer care.
For almost seven decades, philanthropy has fueled cutting-edge cancer research and nurtured innovative patient care programs at The University of Texas MD Anderson Cancer Center. Researchers and clinicians at MD Anderson continue to redefine the standard of cancer care across the globe. Today, the challenge is to seize opportunities and strive toward continued advances in diagnosing, treating and preventing cancer such as personalized therapies and gene-based strategies. Again, philanthropy plays a central role.
Philanthropy: The Gift that Keeps on Giving - Harrison Elias is a tall, lanky eighth-grader who looks forward to his last year of middle school, enjoys football and basketball and plays a mean drum solo - traits of the typcial 14-year-old, one might say.
But Harrison is far from typical.
CABIR Center for Advanced Biomedical Imaging Research - Long before they are large enough to be detected by the most sensitive current imaging techniques, tiny tumors weave a web of new blood vessels to nourish their growth. Juri Gelovani, M.D., Ph.D., chair of MD Anderson’s Department of Experimental Diagnostic Imaging, believes researchers can turn this blood supply against tumors to betray their existence before they can be imaged directly.
Center Focuses on Personalized Cancer Therapies - MD Anderson’s Center for Targeted Therapy (CTT) is in the thick of two great changes in cancer care: developing drug therapies that prey on the molecular vulnerabilities of cancer while largely sparing normal tissue, and personalizing cancer treatments to individual patients. “It’s an amazingly exciting time to be doing what we are doing now,” says Garth Powis, D.Phil., director of the CTT and chair of the Department of Experimental Therapeutics.